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Abstract
Although significant accomplishments have been made in research to understand, diagnose and 
treat Alzheimer’s disease (AD) and its prequel, mild cognitive impairment, over the last two 
decades, a huge amount more remains to be achieved to impact this incurable, terminal disease 
that afflicts an estimated 26.6 million people worldwide. Increasing evidence indicates that early 
diagnosis will be fundamental to maximizing treatment benefits. Moreover, mechanistically-based, 
hypothesis-driven treatment strategies are now emerging to hopefully spearhead future therapy. 
The cross-fertilization of ideas from multiple disciplines will prove key to optimize strategies and 
translate them to meaningful clinical utility, and forms the basis of the current issue focused on 
“Advances in Alzheimer therapy”.
The 10th International Hong Kong/Springfield Pan-Asian Symposium on Advances in 
Alzheimer Therapy, held in Kowloon, Hong Kong, on February 28, 29 and March 1, 2008, 
for the first time integrated across East and West more than 1200 basic and clinical research 
scientists/physicians to impart the latest information to unravel the origin and pathogenesis 
of Alzheimer’s disease (AD) and to both discuss and highlight improvements towards its 
diagnosis and potential treatment by established as well as novel strategies. This unique 
biennial symposium series continues to provide a priceless mechanism to bring under the 
same roof a dichotomy of scientific interests and expertise to specifically focus them on AD 
and related dementias and to disseminate the most current knowledge on recent advances in 
its potential therapy. AD is now recognized as an incurable, degenerative and terminal 
disease that is global – afflicting an estimated 26.6 million people worldwide in 2006, with 
the number growing in an unabated and frightening manner.
In a manner similar to the two prior symposia in this series, the 8th International Montreal/
Springfield Symposium published in Current Alzheimer Research [1], and the 9th 
International Geneva/Springfield Symposium, likewise, published in Current Alzheimer 
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Research [2], we are pleased to publish selected highlights from the Hong Kong/Springfield 
Pan-Asia Symposium in the present issue. Our choice of subject matter encompasses an 
expansive and demonstrative collection of the basic and clinical research that was presented 
at the Symposium. We challenged each of the authors to generate a forward-looking and 
provocative article that would be compelling to read for those both in their immediate field 
and outside of it. We are grateful to have 11 contributions that form the present issue that 
ably accomplish this. Hence, we are individually beholden to the authors for the value of 
their articles, their perseverance in under going peer review, and their patience in awaiting 
publication.
Cholinergic based strategies – what are they, what do they offer and what 
may the future hold?
As detailed by Pepeu and Giovannini (page 86–96) the cholinesterase inhibitor (ChEI) drug 
class was introduced for the symptomatic treatment of AD in 1990s with lofty hopes. 
Efficacy was anticipated from the ‘cholinergic hypothesis of geriatric memory dysfunction’ 
and a plethora of preclinical studies in adult, aged and AD transgenic rodents suggest their 
efficacy derives from augmenting brain acetylcholine (ACh) levels. Wherefore, the now 
accepted clinical effectiveness of the three widely used ChEIs, donepezil, rivastigmine, 
galantamine, in mild to moderate AD may potentially derive from this action alone or a 
combination of this and additional pharmacologic activities remains a matter of opinion, 
which the authors thoughtfully deliberate. The potential that specific ChEIs may provide 
valuable actions via mechanisms that are cholinergically as well as non-cholinergically 
mediated has been proposed. Whether or not the “classical” ChEIs, donepezil, rivastigmine 
and galantamine, generate such actions beyond their expected cholinesterase inhibition that 
contribute to their therapeutic efficacy at clinically achievable concentrations is adjudicated. 
Nevertheless, the authors consider that well-designed multifunctional ChEIs that balance 
useful and potentially synergistic actions related to disease mechanisms still have a 
therapeutic role to play, and provide not only a future conduit for cholinergics in AD, but for 
other indications too, such as mild cognitive impairment, vascular dementia and, possibly, 
for improvement of memory and learning in healthy subjects.
A recent publication [3] concluded that treatment of dementia with ChEIs and memantine 
can result in statistically significant but clinically marginal improvement in measures of 
cognition and global assessment. It is clear that not all patients respond to treatment and yet, 
on average, some 30 to 60% do even though all have an alike diagnosis of mild to moderate 
AD. This has led to debate of the economic benefit of current AD treatment (http://
www.nice.org.uk). Clearly one would expect a variance in drug efficacy between 
individuals, which may be additionally increased by numerous factors, such as the accuracy 
of diagnosis, the disease stage and the quality of patient selection, any imprecision, 
inaccuracy and bias in the neuropsychological measures utilized to assess efficacy, different 
conformities of research sites to conditions of research protocols as well as numerous other 
potentially confounding factors [4–7]. Controlling for many of these at a single site, Venneri 
and colleagues (page 97–111) were able to separate mild AD patients into two groups: ChEI 
responders and non-responders. Mechanisms underpinning the divergent response of the two 
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groups to ChEIs were then assessed and compared to a healthy, matched elderly control 
group utilizing a functional magnetic resonance imaging (MRI) activation paradigm that 
incorporated semantic association and working memory tasks. An understanding of such 
mechanisms opens the door to both providing more rational treatment strategies as well as 
optimizing those currently available.
An alternative approach to augmenting cholinergic neurotransmission by elevating synaptic 
ACh levels with an anticholinesterase is the use of a direct agonist that is selective for the 
muscarinic receptor (mAChR) M1 subtype. This is predominantly expressed in the cortex 
and hippocampus, and remains relatively unchanged in the brain of AD subjects. As 
described by Caccamo and colleagues (page 112–117) in cellular and in vivo models, the 
activation of M1 mAChRs with a safe and well-designed selective agonist not only imparts 
cholinergic-induced improvements in cognition but also activates biochemical cascades 
involved in the induction and control of both Aβ and tau pathology. This contribution 
defines the complex interaction between the cholinergic system, Aβ and tau, and reviews the 
therapeutic promise of M1 agonists as potential disease-modifying agents in AD.
Amyloid based strategies – how can one effectively lower Aβ in a manner 
that is potentially translatable to the clinic?
The amyloid hypothesis underpins perhaps the primary strategy of experimental drugs/
biologicals currently being developed for the treatment of AD. Aβ accumulation in brain can 
clearly be elevated by mutations in amyloid-β precursor protein (APP), presenilin-1or -2 
(PS1 and PS2, respectively) and other genetic polymorphisms/mutations that can lead to a 
similar outcome by either chronically increasing the production of Aβ42 or decreasing its 
clearance. There are multiple potential points of intervention in such a cascade of events. In 
this regard, Tian and colleagues (page 118–131) describe the activity of a combination of 
four herbal extracts, GEPT, to lower brain Aβ levels in APPV717I transgenic mice. Three 
doses of GEPT were administered orally over an 8-month duration, and compared to 
transgenic and wild-type saline controls as well as to transgenic mice administered the ChEI, 
donepezil. In addition to brain Aβ, proteins associated with its generation (BACE1 and 
PS1), those associated with degradation (insulin-degrading enzyme and neprilysin) were 
likewise quantified to define mechanisms that underpin the potential promise of this 
interesting herbal combination.
Whereas the amount of Aβ present in the brain and CSF of AD subjects remains an area of 
intense interest – particularly with regard to any changes relating to treatment or disease 
progression, there is escalating attentiveness as to the molecular forms of that Aβ. The 
contribution of Ito and colleagues (page 132–136) specifically focuses on this facet of Aβ - 
its ability to self-aggregate and form oligomers: multimeric but non-fibrillar forms of the 
peptide. Clearly, the structure of a peptide will impact many physicochemical and hence 
physiological factors that affect its solubility, distribution and biological actions – 
particularly on synapses that have consistently been noted to be exceptionally vulnerable to 
multiple forms of Aβ. In this light, Ito and colleagues examined the histochemical 
localization of oligomer Aβ in AD brains to elucidate its role in the disease process.
Martínez et al. Page 3





















Although amyloid plaques are a critical hallmark of AD, the disease plainly involves more 
than Aβ. Neurofibrillary tangles, the other primary hallmark that are generated from aberrant 
tau, together with numerous induced secondary factors conjointly impact the disease course. 
Micoglial activation exemplifies a secondary event that can potentially drive the disease 
process consequent to the release of microglia-derived neurotoxic factors, which can 
instigate a vicious self-propagating cycle between up- and downstream processes. Imaging 
and quantifying these in living brain to elucidate their interactions during disease 
progression as well as treatment strategies is the topic of the contribution by Makoto 
Higuchi (page 137–143). The brains of AD transgenic mice were examined by high-
resolution positron emission tomography (PET) following administration of specific probes 
for amyloid, tau and microglial activation as neuroimaging biomarkers to follow these events 
in living brain.
An early hypothesis-driven clinical trial that, in large part, aimed to test the amyloid 
hypothesis was the immunization of AD patients with synthetic Aβ42 (AN1792) in a 
randomized, double-blind, placebo-controlled phase 2a study. In prior preclinical studies, 
immunotherapy with human Aβ42 stimulated the clearance of amyloid plaques and reduced 
AD-associated cognitive declines in mouse model of AD. Albeit that the AN1792 trial was 
halted following reports of encephalitis, it has nevertheless provided a wealth of valuable 
information. Vellas and colleagues (page 144–151) add to this in an analysis of subjects 
from the original trial some 4.6 years after immunization in which multiple measures were 
undertaken to determine both cognitive and pathological differences between AN1792 
antibody responders and placebo-treated patients.
Tau based strategies – an invariable feature of AD and a drug target to 
impeded disease progression
Other crucial hypothesis-driven strategies to slow or potentially halt the progression of AD 
are being developed as, likely, a combination of approaches may ultimately prove most 
effective, as found in other diseases. The hyperphosphorylation of tau in AD brain, leading 
to the development of neurofibrillary tangles, is an unambiguous feature of AD and the 
focus of several therapeutic strategies. Comprehending the complex interactions between 
aberrant tau aggregation, synaptic loss and cholinergic system dysfunction is fundamental in 
understanding the disease process and developing viable intervention approaches. This is the 
focus of the contribution provided Belarbi and colleagues (page 152–157), who have 
developed a THY-Tau 22 transgenic mouse model that reliably recapitulates the Alzheimer-
type neurofibrillary degeneration in the absence of amyloid deposits. This mouse develops 
age-dependent tau pathology that leads to synaptic dysfunction and impairments in learning 
and memory, and is utilized by the authors to elucidate tau/cholinergic system relations.
Novel approaches to augment the cholinergic system – exquisitely 
vulnerable and absolutely vital
Trophic support is indispensable to the health and survival of many types of neurons, and 
particularly for cholinergic ones. As described by Covaceuszach and colleagues (page 158–
Martínez et al. Page 4





















170), the neurotrophin family member, nerve growth factor (NGF), exerts a wide and crucial 
range of physiological actions on basal forebrain cholinergic neurons, which constitute its 
primary target. The basal forebrain cholinergic system provides key projections to the 
cerebral cortex and hippocampus that support learning and memory, but appears particularly 
vulnerable to disruption in AD. Augmenting NGF has, hence, provided an attractive 
therapeutic option to preserve or rescue the cholinergic system in AD, but safely and 
effectively enacting this strategy has proved difficult. In this light, Covaceuszach and 
colleagues describe an engineered mutein of human (h)NGF, hNGF-61, that is bio-
equivalent to but can be differentiated from hNGF, to make it traceable and thereby facilitate 
the determination of optimal dosing and distribution. The efficacy of hNGF-61 is described 
in an AD mouse model following its non-invasive intranasal administration.
New models and diagnostics – opening new windows to understand the 
basis of, diagnose and treat AD
Although AD is clearly a human neurodegenerative condition, rodents, and in particular 
transgenic mice expressing human proteins relevant to the disease and occasionally with 
specific proteins deleted, have proved to be powerful tools to both aid elucidate molecular 
mechanisms underpinning the disease process and to assess the potential efficacy of 
therapeutic interventions. In this light, Sarasa and Pesini (page 171–178) provide interesting 
insight as to how specific natural non-trangenic animal models could valuably contribute to 
AD research and drug development. Notably, the chick embryo and the dog have, among 
numerous attributes, an enzymatic machinery for processing APP that is almost identical to 
that of humans. The authors review the characteristics and potential utility of a wide array of 
natural models, which with versatility replicate particular aspects of AD, and could aid in 
moving the field forward on several fronts.
To optimally assess the efficacy of a disease modifying therapeutic strategy one must utilize 
it early, rather than late, in a disease process, as has been demonstrated in other conditions 
epitomized by cancer and heart disease. Early diagnosis is thus key. As reviewed by 
Pihlajamäki and colleagues (page 179–185), the reliable early diagnosis of AD, however, is 
one of the most interesting as well as challenging areas of current AD research. The 
identification of individuals with prodromal AD – mild cognitive impairment (MCI), and in 
particular the amnestic subtype of MCI, representing an intermediary state between normal 
aging and clinical AD in which memory impairment is subtle and structural atrophy 
insignificant - would provide subjects with sufficient conserved function remaining. It is in 
this frontier area that structural and functional MRI are making inroads to provide the tools 
required to select out and follow the disease process.
In closure, this issue captures a window, in the form of 11 stimulating articles, of a thought-
provoking symposium focused not only on the latest advances in AD research, diagnosis and 
treatment but also on identifying the most critical gaps in our knowledge that require filling. 
We are appreciative of the numerous scientists that aided in the peer-review process and 
wish to thank the organizers of the meeting, sponsors and publisher and staff of Current 
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Alzheimer Research for their cooperation and efforts in the creating of this issue (http://
www.bentham.org/car/).
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